series-a
Stage
2021
Founded
1
Investors
About
PanCancerT is a biotechnology company developing next-generation T cell receptor (TCR) therapies for solid tumors, based on pioneering research from Erasmus MC. Their lead product, PCT1:CO-STIM, aims to treat triple-negative breast cancer, a cancer type with limited treatment options.
Explore PanCancerT's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.